Introduction
Dichloro(2-chlorovinyl)arsine was synthesized in 1903 by Julius Arthur Nieuwland at Catholic University (Washington, D.C.) by reacting acetylene and arsenic trichloride (1) . Winford Lee Lewis synthesized and purified dichloro (2-chlorovinyl) arsine by adding hydrogen chloride before distillation and detailed the toxicity of the compound (2) . Dichloro(2-chlorovinyl)arsine was subsequently named Lewisite.
Lewisite is an oily, colorless liquid in its pure form. It can appear amber to black in its impure form with an odor resembling geraniums (3, 4) . It is a highly toxic vesicant, causing irritation of the skin and mucous membranes within minutes after contact and can blister within hours (3) (4) (5) (6) . In addition to the blistering effects, dermal exposure to Lewisite can result in elevated urinary arsenic levels and significant loss of blood pressure in what is called "Lewisite Shock" (7) . A low-dose exposure to skin (14 µg) can cause vesication, and higher doses (30-50 mg/kg) can lead to death (4) . Lewisite has been stockpiled as a chemical warfare agent and has no medical or other use.
Lewisite went into production in 1918, which was too late for battlefield deployment in World War I (WWI). More than 45,000 tons of Lewisite are estimated to have been produced since 1903 (2) . Between WWI and World War II (WWII), at least 11 countries produced or possessed Lewisite (2) . After WWII, most of these countries disposed of their Lewisite stockpiles. There are a few sites in the U.S. where Lewisite has been stored while awaiting disposal or was discovered in former military facilities (4, 8, 9) . Several nations have allegedly used Lewisite-or Lewisite-mustard-containing weapons in past conflicts (4, 10) . Therefore, concerns remain that Lewisite might be used to cause large numbers of injuries and deaths.
Urban and von Tersch (11) used ab initio molecular orbital calculations to predict that Lewisite would consist predominantly of the trans-isomer, very little of the cis-isomer, and negligible amounts of the geminal-isomer. Smith et al. (12) interpreted 1 H and 13 C nuclear magnetic resonance spectroscopy data and gas chromatography-mass spectrometry (GC-MS) analysis of the 1,2-ethanedithiol derivative to imply that the Lewisite samples they analyzed consisted of 95.2% transisomer, 2.7% geminal-isomer, less than 1% cis-isomer, and a small remaining unidentified fraction. In either case, the transisomer is by far the predominant isomer in production materials.
The primary metabolite of Lewisite in animals is the hydrolysis product chlorovinylarsonous acid (CVAA) shown in Figure 1 (9, 13) . Lewisite is rarely found in the environment because of the rapid rate of hydrolysis to CVAA (14) (15) (16) (17) . In the environment, CVAA may be oxidized to 2-chlorovinylarsonic acid (CVAOA) (14) , which may also be found in urine (19) . Both CVAA and CVAOA still retain the toxic properties of Lewisite, albeit at lower potency (17) (18) (19) (20) . CVAA and CVAOA are not natural environmental forms of arsenic and can be detected in urine only after exposure to Lewisite or CVAA.
An acute exposure to Lewisite in rats can result in elevated total arsenic in urine as shown in work presented here and elsewhere (21) . Total arsenic may be determined by inductively coupled plasma (ICP)-MS (22, 23) . However, determination of total arsenic does not differentiate between CVAA, inorganic species, and metabolically derived organoarsenic species. In order to differentiate between the forms of arsenic found in different compounds by ICP-MS, a separation technique must be employed (24) (25) (26) (27) .
Several analytical methods have measured CVAA to determine Lewisite exposure. Szostek and Aldstadt (28) used 1,3-propanedithiol or 1,2-ethanedithiol derivatization with solidphase microextraction (SPME)-GC-MS to examine CVAA in soil samples from a military installation. Wooten et al. (5) determined CVAA in urine by using GC-MS for the 1,3-propanedithiol derivative. Wada et al. (18) used reversed-phase liquid chromatography (HPLC)-tandem MS to analyze the degradation products of Lewisite in soil extracts. Although GC-MS and SPME-GC-MS methods may have very good sensitivity, ICP-MS is highly sensitive due to matrix destruction and high ionization efficiency as a result of the plasma temperature. GC-MS and SPME-GC-MS have advantages but may also require derivatization and SPME steps that add to sample preparation time.
Kinoshita et al. (19) used a C 8 reversed-phase column for HPLC-ICP-MS analysis of CVAA and CVAOA in mouse urine after only dilution and pH adjustment sample preparation steps; they used oxygen introduced as an ICP-MS reaction cell gas to convert As + (mass 75) to AsO + (mass 91) to avoid interference from ArCl + (mass 75). Addition of cell gases suppresses ICP-MS polyatomic interference problems as well as the analyte signal. We optimized the instrument and chromatography conditions to minimize formation of ArCl + and to resolve chloride and, thus, any minimal remaining ArCl + from arsenicals of interest. We, therefore, eliminated the need for a cell gas and the consequential suppression of arsenic signal in the method presented here. 
Experimental Materials
The U.S. Army Medical Research Institute of Chemical Defense (Aberdeen Proving Ground, MD) provided CVAA at a concentration of 746 µg/mL. Lots of the L1 standard (one chlorovinyl group bonded to the arsenic atom) received 95-98% purity. Purity on the basis of arsenic content was verified upon receipt using our established total arsenic method (22) . Ultrapure >18 MΩ• cm water and organic-free water came from an Aqua Solutions water system (Jasper, GA). Tetrabutylammonium hydroxide (TBAH, 40% aqueous solution), succinic acid, 2-propanol (IPA, electronics-grade), Fluka sodium cacodylate (DMA), and arsenobetaine (AsB) were purchased from Sigma Aldrich (St. Louis, MO). Sodium arsonoacetate (AA) was purchased from TCI America (Portland, OR). Inorganic arsenic [As(III) and As(V)] standards were purchased from SPEX Certiprep (Metuchen, NJ). Monosodium acid methane arsonate was obtained from Chem Services (West Chester, PA). GFS Chemicals double-distilled ammonium hydroxide and nitric acid were obtained from Fisher Scientific (Suwanee, GA). Tamapure 10 double-distilled 35% hydrogen peroxide was obtained from Moses Lake Industries (Moses Lake, WA).
Preparation of standards, quality controls, and samples
Aqueous solutions of the CVAA intermediate standards were prepared by dilution to concentrations of 100, 1608, 4026, 7962, and 31,847 µg/L. Quality control (QC) intermediate standards were prepared at 796, 12,170 and 20,018 µg/L. Shortterm storage of the CVAA spiking solutions was at 2-4°C. Longterm storage (> 4 days) was at -20°C. 2-Chlorovinylarsonic acid standards (CVAOA) were prepared from CVAA standards by hydrogen peroxide oxidation as described by Kinoshita et al. (19) . The instrument response of five individual base urine samples spiked at a concentration of 35 µg/L of CVAA were compared to the response from five base urine samples spiked with the same concentration of CVAA that had been oxidized to CVAOA on two different days to confirm equivalence.
The intermediate internal standard solution was made by adding 300 mg of sodium arsonoacetate to 1 L of water. The diluent was prepared by diluting 4.0 mL of the intermediate internal standard solution with mobile phase to a final volume of 1.0 L to give a final concentration of 1.2 mg/L of sodium arsonoacetate. The pH of the diluent was adjusted to 5.5 and stored at 2-4°C.
Urine samples from anonymous donors were collected in pre-screened polypropylene urine cups. Total arsenic concentration for each sample was determined by inductively coupled plasma-dynamic reaction cell (ICP-DRC)-MS (23) . The urine samples with the lowest concentrations of arsenic were pooled for use as base urine.
The matrix-matched CVAA standards and quality controls were created by spiking 400 µL of base urine with 40-µL aliquots of each of the intermediate CVAA calibration or QC solutions. Then, 1000 µL of diluent with internal standard sodium arsonoacetate was added to each standard or QC for a total volume of 1440 µL. The final standard concentrations of CVAA in urine were 9.09, 146, 366, 724, and 2895 µg/L with quality control (QC) concentrations of 72.4, 1106, and 1820 µg/L. The centrifuge tubes were capped, vortex mixed briefly, and centrifuged for 4 min at 1.5 × 10 4 × g. A 0.85-mL aliquot of the supernatant was transferred to an autosampler vial and capped. Urine samples were prepared for analysis in a similar manner, except that the substitution of 40 µL ultrapure water came in place of the CVAA standards.
Frozen rat urine collected over the final hour of the 4-h time periods was obtained from a 2004 Lewisite exposure study (21) . Twelve rats were included in the study. Four rats were exposed percutaneously to 0 (control group), 2.0, or 10 mg/kg of Lewisite according to an approved animal protocol including anesthesia, buprenorphine administration to prevent pain, and euthanasia. Urine was thawed prior to analysis.
Mobile phase and diluent preparation
The LC separations were accomplished with an isocratic mobile phase consisting of 2% (v/v) IPA, 11.6 mM TBAH, and 5.0 mM succinic acid with the pH adjusted to 5.5 using nitric acid.
Instrumentation
Chromatography was performed using a Perkin Elmer (Waltham, MA) 200 series HPLC (including pumps and degasser) with autosampler at 4°C and column oven at 30°C. Supelco Ascentis RP-Amide polar-embedded reversed-phase HPLC columns (Sigma Aldrich) with a 4.6-mm internal diameter and lengths of 50, 100, and 150 mm were used for chromatographic separations. The flow rate and injection volume were 1 mL/min and 20 µL, respectively. Chromatographic data acquisition was controlled using Chromera version 1.2 software (Perkin Elmer).
The eluent was introduced into a Perkin Elmer ELAN DRC II ICP-MS through a Glass Expansion Twister 50-mL cyclonic spray chamber and SeaSpray nebulizer for HPLC (Pocasset, MA). The instrument was operated in evacuated cell mode at 1,550 W radio frequency (RF) power with nebulizer gas (typically 0.95 mL/min), and other parameters optimized. The ICP-MS was controlled using ELAN version 3.4 software (Toulouse, France).
Integration of data
Peaks representing the arsonoacetate internal standard, CVAA, and other metabolites were integrated by reprocessing the data with Chromera 1.2 software to obtain peak-area/internal standard area ratios. A concentration regression model was generated using the area ratios versus standard concentrations. The standard concentration regression model was used to calibrate peak-area/internal standard area ratios for samples with previously unknown concentrations.
Determination of method detection limits
The method detection limit (MDL) was determined based on 3 times S 0 , standard deviation at 0 µg/L CVAA concentration (31) . S 0 was approximated as total standard deviation [S t = (S (within run) 2 + S (between run) 2 ) ½ ] because Chromera was not capable of integrating a base urine CVAA baseline. Therefore, S (within run) was calculated from the integrated results of 20 individual base urine samples spiked with the lowest concentration standard and run as samples versus the same blank and calibration standards in the same run. S (between run) was calculated by extrapolation to 0 µg/L CVAA concentration from a regression plot of between run standard deviations from 20 runs on 14 different days versus concentrations of the lowest 3 standards (32) . Limit of quantitation (LOQ) was determined as 10 × S 0 (32).
Results and Discussion
In our initial studies, we examined the purity of the CVAA standards used to quantify unknown samples. We determined as much as 4% arsenious acid impurity relative to the mass of CVAA in one standard preparation. It is probable that this small fraction of inorganic As(III) resulted from hydrolysis of unreacted AsCl 3 remaining from the synthesis described briefly in the introduction. On this basis, it is possible that AsCl 3 may have been one component of the unidentified fraction of Lewisite described by Smith et al. (12) .
To ensure that analysis of CVAA would not be affected by arsenic compounds commonly found in urine, initial studies were carried out using Supelco Ascentis RP-Amide columns (150 × 4.6 mm, Figure 2A ) with 3-µm particle sizes to resolve, identify, and assign major peaks from spiked or pre-existing arsenic compounds in urine. Mass 35 (Cl + ) and mass 75 (As + or ArCl + ) chromatograms of standards in urine with a 150-mm column are shown in Figure 2A . When using the 150-mm column, monomethylarsonate (MMA V ), DMA, As(V), As(III), AsB, and AA were resolved from CVAOA and CVAA. The main objective of this method was to rapidly analyze samples for CVAA without regard to isomers, although CVAA is predominantly the trans-isomer, while maintaining its elution separate from AA and the compounds in urine that could otherwise interfere with the accuracy of the results.
As can be clearly seen from Figures 2B and 2C , CVAOA, CVAA, and AA were still resolved from other arsenic standards in the chromatograms obtained by using 100-mm or 50-mm, 3-µm particle columns. To decrease the CVAOA and CVAA analysis time, the 50-× 4.6-mm column with 3-µm particle size was employed. The analysis time decreased to 4 min as shown in Figure 2C . The chloride peak was still adequately resolved from CVAA, CVAOA, and AA peaks in chromatograms obtained using all column lengths. Urine contains enough chloride to potentially create a polyatomic isobaric interference by reacting with argon to produce ArCl + (m/z 75). Although chloride clearly eluted prior to CVAA and CVAOA, ArCl + (m/z 75) was not formed to a degree that was significant relative to the arsenic concentrations in standards that had been spiked into human urine nor relative to arsenicals present in pre-exposed rat urine samples and to only a small degree in urine from rats exposed to Lewisite. This was apparent by comparing the 35 Cl + traces to the m/z 75 traces.
It is probable that the use of platinum tipped cones, high RF power, optimization of nebulizer gas for low oxides, and 2% isopropanol in the mobile phase (33) , all of which contribute to a hotter plasma at the cone, resulted in very low ArCl + ion formation. Ferguson and Houk (34) describe a plasma condition in which fewer polyatomic ions occur in the mass spectrum as a result of the kinetic gas temperatures (T gas ) value. These values correspond to the measured dissociation constant (K d ) for a given polyatomic ion that is higher than the expected 5500-6000 K (34), such as may be the case when the plasma is optimized as described here. Therefore, the need for a cell gas or nitrogen carrier gas (35) to eliminate the ArCl + ion was obviated, and the Dynamic Reaction Cell™ (DRC), which is typically used to remove isobaric interferences, was operated in evacuated mode.
Twenty calibration curves, over the range of 9.09-2895 µg/L, were run over a six-week period. Correlation coefficients were at a minimum > 0.99 and typically were > 0.999. Anticipating the need for expanded analytical capacity in response to a large-scale emergency, we must achieve acceptable reproducibility and accuracy of results following transfer of the method between instruments and analysts. The method was transferred to a different HPLC-ICP-MS for an interinstrument and interanalyst comparison. A regression plot of the calibration standards and quality controls resulted in a slope of 1.03 and a correlation coefficient of 0.9997, which indicate that comparable results can be obtained with separate instruments and different analysts.
t-Test of results from the comparison of instrument response and calibration of five CVAA standard spikes in base urine to five spikes of CVAOA on two different days demonstrated no statistically significant difference in instrument response on the basis of arsenic (p = 0.15, p = 0.68, respectively).
The MDL was determined to be 1.3 µg/L as CVAA (1.4 µg/L CVAOA) on the basis of compound mass at the dilution described. The LOQ was calculated as 4.2 µg/L as CVAA (4.6 µg/L CVAOA) (32) . The MDL and LOQ are of the order of concentrations of compounds reported on the basis of arsenic typically determined in the U.S. population as a result of exposure from food, water, and other environmental sources (36) . Therefore, the method is sufficiently sensitive for determination of CVAA or CVAOA arsenic in urine at concentrations similar to those of species that are found as a result of common environmental arsenic exposure.
As part of the validation process, QC samples were analyzed in 20 independent runs over a 6-week period. QC was evaluated according to National Center for Environmental Health, Division of Laboratory Sciences quality control policy, and was consistent with the Westgard criteria (37, 38) . QC was found to be acceptable at all three levels as exemplified in the plot of data from the lowest concentration QC in Figure 3 . The average low, medium, and high QC results (70.2, 1104, and 1841 µg/L, respectively) were in good agreement with the calculated concentrations of 72.3, 1106, and 1820 µg/L. In addition, relative standard deviation for the low QC sample was less than 6%, and the medium and high QC samples were less than 3%. Twenty urine samples from unexposed individuals were spiked with CVAA, which resulted in concentration levels ranging from 10 to 900 µg/L. Each concentration level was spiked in five individual urines, and the mean, accuracy, and reproducibility were determined as shown in Table I . The average recovery, a measure of the accuracy of the analysis, ranged from 96 to 101%. The relative standard deviation values for the four concentrations were less than 6%. The accuracy and reproducibility of the spiked individual urine samples demonstrate the applicability of this method across a diverse range of urine matrices and concentrations.
One hundred urine samples from individuals with no known exposure to Lewisite were analyzed to establish a background reference range in the unexposed population and to ascertain whether any false positives would result due to variation in the chloride concentrations or environmental and dietary arsenic that might be passed from one person to another. There were no detectable levels of CVAA or CVAOA in urine from individuals without any known exposure to Lewisite.
To determine method applicability to analysis of urine excreted after exposure to Lewisite, urine samples collected from rats exposed in a 2004 study (21) were analyzed. Chromatograms resulting from analysis of urine from a rat immediately prior to exposure and at 19-20 h after exposure to the low Lewisite dose on a 50 × 4.6-mm internal diameter column are shown in Figure  4A -4B. No As peaks eluted in the vicinity of CVAA or CVAOA retention times during the analysis of urine obtained from rats immediately before Lewisite exposure ( Figure 4A ) or from control rat urine collected at any time point. The As(III) peak is visible in Figure 4A , but the small As(V) peak had insufficient intensity for quantification, which indicates stability of As(III) to oxidation over the 1-h urine collection time, while thawed for analysis and frozen for 5 years. The DMA and the AA peaks are the only other peaks visible above baseline in the chromatogram from rat urine obtained immediately prior to exposure.
The chromatogram from analysis of a rat urine sample collected 19-20 h after the low-dose Lewisite exposure (the time at which concentration of total arsenic and CVAA excreted had reached their zeniths) (21) in Figure 4B is markedly different from the rat urine collected before exposure. A CVAA concentration of 759 µg/L was determined from the analysis of the urine collected during this time period, which indicates significant transdermal and systemic Lewisite absorption. The concentration of CVAA decreased to 314 µg/L in urine collected between 23 and 24 h after exposure.
Most of the urine samples from exposed rats that were analyzed contained CVAOA with little or no CVAA remaining, though inorganic As(III) remained unoxidized ( Figure 4C ). With one exception, these samples also had less than 1-mL total volume, which led to a high ratio of surface area exposed to air for the volume. The analysis of urine from a rat that received a high Lewisite dose on a 150 × 4.6-mm internal diameter column is shown in Figure 4C . Kinoshita et al. (19) reported that CVAOA but almost no CVAA remained in a 24-h collection of urine from a mouse exposed to CVAA. The CVAA and CVAOA metabolites observed in chromatograms from both low and high dose rat urine samples in Figures 4B and 4C were, therefore, expected and confirm the applicability of the method to measurement of these metabolites as a result of Lewisite exposure. It was not clear whether the CVAOA occurred as a metabolite, as Kinoshita et al. (19) considered possible, or if it was generated during the period of collection and analysis in which the mouse or rat urine was thawed. However, these findings indicate that the vinyl arsenic in CVAA is much more labile to oxidation than inorganic As(III). Therefore, the ability to determine the oxidized metabolite is very important to Lewisite exposure assessment. CVAOA concentrations were 1634 µg/L CVAOA (equivalent to 1494 µg/L on the basis mass of CVAA on a molar basis) in rat urine collected between 19 and 20 h after the high dose Lewisite exposure. The urine concentration then decreased to the equivalent of 1096 µg/L CVAA in urine (1199 µg/L CVAOA) collected between 23 and 24 h after exposure. These data illustrate the dose-dependent increase in combined CVAOA and CVAA excretion after exposure to Lewisite. The data also demonstrate the importance of analyzing both CVAA and CVAOA as a measure of Lewisite exposure, especially considering the ambiguity in the literature on the extent of successful derivatization of CVAOA with dithiols for gas chromatography (39) .
It is beyond the scope of this study to fully explain whether the urine chloride concentration increased sufficiently to cause the appearance of the small ArCl + peak in Figure 4B -4C as a result of Lewisite and AsCl 3 hydrolysis alone. However, under the instrumental conditions described, the ArCl + peak was small and resolved from CVAOA and CVAA, so ArCl + was not a factor that could compromise the CVAA or CVAOA results even when chloride excretion was sufficiently elevated to cause detectable ArCl + formation.
Kinoshita et al. (19) noted several major unknown and unresolved organoarsenic metabolites in mouse urine after exposure to CVAA. In this study, we analyzed urine samples from rats that had been exposed to Lewisite; the samples were collected and stored frozen five years earlier. We observed large increases in peak area for the metabolites that eluted in less than 1.0 min ( Figure 4B ) compared to pre-exposure urine samples. Determining whether all of the relative peak areas of the arsenic-containing species are a function of active metabolism of Lewisite or due to other causes is beyond the scope of this study. However, the peak areas of As(III) and DMA increased 867% and 862%, respectively ( Figure 4B ), in urine of the rat that received the low Lewisite dose and 256% and 381%, respectively, in urine of the rat that received the high Lewisite dose ( Figure 4C ). Because these particular metabolites have been described as stable while frozen (29, 30) and no oxidation of As(III) to As(V) was observed, it is highly unlikely that these metabolites were artifactual.
In both chromatograms, an additional major unidentified metabolite was apparent. The unidentified metabolite that eluted at 1.94 min from the 150-mm column ( Figure 4C ) had peak intensity intermediate between As(III) and DMA in the rat given a low Lewisite dose. Based on arsenic counts/s, in the urine of the rat exposed to the high Lewisite dose (Figure 4C ), the unidentified peak had more than five times the intensity of the DMA peak. Taken together, these could indicate possible Lewisite dose-dependent metabolic or excretion differences for some metabolites. Oxidation of our standards with hydrogen peroxide did not result in a peak that coeluted with the major unidentified metabolite; nor did monitoring 34 S and 78 Se along with the mass 75 chromatogram identify it as a sulfur or selenium conjugate. Further investigation into the identity of this metabolite is warranted, such as the possibility of methylation of the chlorovinyl-arsenic atom because some organoarsines have been found to be methylated microbially in soil (40) . The identification of all of the metabolites of Lewisite is beyond the scope of this study, but those determined here indicate that depending on dose, not all of the metabolic arsenic from Lewisite exposure was reflected in the principal CVAA and CVAOA metabolites. However, As(III) and DMA excretion did not reflect the metabolic dose-dependence characteristic of CVAA and CVAOA demonstrated in this study. Further, though excretion of the unidentified metabolite increased with dose, its relative intensity was not as high in urine from the rat administered the low Lewisite dose as in the rat administered the high Lewisite dose.
Without regard to the latter findings, the chromatographic peaks for CVAA and CVAOA were well-resolved and, thus, still quantifiable even in the presence of these additional metabolites and with the ArCl + peak apparent only in urine from Lewisiteexposed rats. Therefore, CVAA and CVAOA may be quantified using this method even when increased concentrations of these additional characterized and uncharacterized arsenical metabolites are present. Though further study into dose-dependent metabolism of organoarsenic compounds is needed to clarify these issues, for the purpose of rapidly determining Lewisite exposure, CVAA and CVAOA remain the species of choice for their utilization as major biomarkers of Lewisite exposure.
Conclusions
A high-throughput LC-ICP-MS method for analysis of CVAA, a major urine metabolite of Lewisite, and its oxidation product, CVAOA, has been developed and is capable of 12 samples/h and 96 samples per 8-h workday throughput. The data indicate that this method provides a rapid, robust, and sufficiently sensitive means to assess Lewisite exposure via the CVAA and CVAOA metabolites in urine over a wide range of concentrations. The method is simple, accurate, and reproducible. Small volumes of urine (400 µL), simple sample preparation, and interinstrument reproducibility establish capability for transferring the method to additional public health laboratories for expanded capacity in the event of small-or large-scale Lewisite exposures.
